# Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive Tract

> **NCT01116622** · PHASE1 · COMPLETED · sponsor: **Dartmouth-Hitchcock Medical Center** · enrollment: 24 (actual)

## Conditions studied

- Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus)

## Interventions

- **DRUG:** Bexarotene (Targretin®)
- **DRUG:** Erlotinib (Tarceva™)

## Key facts

- **NCT ID:** NCT01116622
- **Lead sponsor:** Dartmouth-Hitchcock Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-10-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01116622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01116622, "Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive Tract". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT01116622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*